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INTRODUCTION
Urothelial carcinoma (UC) of the urinary bladder is the most common malignancy of the genitourinary tract and the sixth-most common cancer in men worldwide. [1] Approximately 75% of patients with UC initially present with nonmuscle UC, which is confined either to the mucosa as a papillary (stage pTa) or to invasion limited to the lamina propria (stage pT1). [2] Nonmuscle-invasive UC is a heterogeneous group of tumors with different rates of progression ranging from 0.8% to 45% in 5 years, [3] compared to muscle-invasive UC. UCs develop in several phases and require the presence of multiple carcinogenic factors, which can activate genes that stimulate cell proliferation or inhibit tumor suppressor genes. [4] Among the latter, p53 functions include the inhibition of cell growth and response to DNA damage and act as a gatekeeper to apoptotic pathways. Alterations of p53, due to either mutation or protein dysregulation, are the most common genetic alterations in the UC. [5] The murine double minute 2 (mdm2) proto-oncogene plays a key role in regulating the p53 pathway by binding directly to the p53 protein.
The overexpression of mdm2 leads to decrease in p53 activity by the ubiquitination system. [6, 7] The INK4a-ARF locus encodes two structurally and functionally different two-cell cycle regulatory proteins-p16 and p14 ARF in humans. [8] p14 ARF is a tumor suppressor protein that is triggered by apoptotic cell death and/or cell cycle arrest on oncogenic stress. [9, 10] Initially, both the proapoptotic and cell cycle regulatory functions of p14 ARF were proposed as being strictly dependent on the presence of a functional p53/mdm2 signaling axis. However, a number of recent reports have indicated that p14 ARF is capable of engaging p53-independent signaling events in the regulation of cell cycle arrest and apoptosis induction. [9, 11, 12] p14 ARF binds the mdm2 proto-oncogene and inhibits This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work noncommercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
For reprints contact: reprints@medknow.com mdm2-induced p53 degradation, resulting in an increase in p53 levels. [8] A variety of caspases with an apoptotic function, which are aspartate-specific cysteine proteases have been described to date. In accordance with the cascade of activation, caspases can be subdivided into initiators and effectors. Caspase-8 is located in the cytosol and is known as the initiator caspase of the extrinsic apoptosis pathway, which is triggered by several apoptosis signals related to the death receptor. Once activated, caspase-8 typically cleave downstream caspases, which leads to apoptosis in tumor cells. [13] A defect in caspase-8 expression may contribute to the disruption of apoptotic pathways, which was confirmed by the down-regulation of caspase-7 in some tumors and cell lines. [14, 15] In addition, the loss of caspase-8 expression was involved in the resistance to apoptosis, and was associated with malignant phenotypes and clinical outcomes. [14] [15] [16] Studies about the protein expression of caspase-8, p53, mdm2, and p14 ARF were limited in UC. [8, [17] [18] [19] [20] [21] In the present study, we aimed to determine the expression profiles of the proteins in pTa and pT1 UCs and the effectiveness of these protein panels in routine practice. According to the best of our knowledge, this is the first study to determine the combined expression of the proteins in UCs.
SUBJECTS AND METHODS

Patients and tumor tissue samples
The present study was approved by the Institutional Review Board of Pamukkale University (Denizli, Turkey). We analyzed archival tumor samples of pTa, and pT1 UC obtained from 50 patients who underwent a transurethral resection (TUR) at the time of diagnosis between February 2005 and March 2011 at Pamukkale University Hospital. Hematoxylin and eosin stained sections of all tumor samples were re-evaluated for grading and pathological staging (pT) according to the 2004 World Health Organization and the 2002 tumor node metastases revision, respectively. [22] Clinical information for each patient, such as age, sex, tumor recurrence, and progression, was obtained from electronic medical records or hospital charts. Serial sections (5 µm thick) containing representative tumor tissue enriched with tumor cells were used in immunohistochemistry (IHC) staining.
Immunohistochemical analysis
The primary antibodies used in this study and their positive controls are summarized in Table 1 . IHC staining was performed using an ultraView Universal DAB detection kit (Ventana Medical Systems) in an automated staining system (BenchMark XT, Ventana Medical Systems, Tucson, AZ, USA). The nucleus was counterstained with hematoxylin. In each staining run, positive and negative controls were included. All IHC-stained slides were evaluated by a pathologist (nerve-sparing type) who was blinded to the associated clinical and pathological information. The percentages of tumor cells that showed nuclear stained with chromogen (brown) for caspase-8, p53, mdm2, and p14 ARF were recorded. Cutoff values for nuclear caspase-8, p53, mdm2, and p14 ARF were determined by ROC curve analysis as follows caspase-8 (10%), p53 (10%), mdm2 (20%), and p14 ARF (10%). Assessment of cytoplasmic IHC staining with caspase-8 in the tumor cells was based on both qualitative and quantitative staining. First, the intensity of the IHC staining with caspase-8 was graded as follows 0 = negative; 1 = weak; 2 = moderate; and 3 = strong. Second, the rate of caspase-8 staining was graded as follows 0 < 5%; 1 = 5%-25%; 2 = 26%-50%; 3 = 51%-75%; and 4 >75%. A final score was determined by adding the two scores above, yielding a range from 0 to 7. Scores 0-3 were defined as negative/weak expression; 4 as a moderate expression; and ≥ 5 as a strong expression.
Statistical analysis
Statistical analysis was performed using the SPSS software (version 16.0; SPSS, Inc., Chicago, IL, USA). The relationship between protein expression and major clinicopathological parameters (such as tumor stage, tumor grade, recurrence, and progression) was assessed using the Chi-square test. The kappa consistency (κ) check was used quantify the level of measurement agreement between these four antibody expression status. For all analyses, P < 0.05 was considered statistically significant.
RESULTS
Patients' characteristics
A total of 50 patients were analyzed. The mean age was 63.9 ± 1.8 years at the time of diagnosis with a 4:1 male-to-female ratio. Half of the cases (50%) included the muscularis propria in the TUR specimens.
Low-grade UCs were observed in 22 (44%) cases while high-grade UCs were detected in 28 (56%) of the cases. Nineteen (38%) and 31 (62%) cases were classified as noninvasive (pTa) and invasive (pT1) UCs, respectively. Of the pTa cases, 18 were low grade and one was high grade, while of the pT1 cases 4 were low grade and 27 high grade. The mean follow-up period was 55.32 ± 35.13 months after the time of diagnosis. Of 50 patients, 12 (24%) had a recurrence of UC at a median of 9 months (range, 3-63 months). The median follow-up for thirteen (26%) patients with progression was 23 months (range, 4-67 months). All patients were still alive.
Immunohistochemical analysis
Cytoplasmic caspase-8 expression was significantly higher in pT1 UCs while nuclear caspase-8 expression was significantly higher in pTa UCs (P = 0.005 and P = 0.011, respectively) [ Table 2 ] [ Figure 1 ]. Furthermore, cytoplasmic caspase-8 expression was significantly higher in high-grade UCs (P = 0.035). However, no significant relation was detected between nuclear caspase-8 expression and tumor grade (P > 0.05) [ Table 3 ]. No significant correlation was detected between p53, mdm2, and p14 ARF expression, and pathological stage or grade (P > 0.05 for all) [ Tables 2 and 3 Table 4 ]. It was not found a significant association between the expression of p53, mdm2, p14 ARF , and caspase-8 proteins and clinicopathological characteristics including recurrence and progression. However, the patients who had recurrence were positive for both p53 and mdm2 or either p53 or mdm2 when the expression of p53 was combined with mdm2 expression (P = 0.025) [ Table 5 ].
DISCUSSION
To the best of our knowledge, the present study is the first to analyze the prognostic significance of the combination of four IHC markers: caspase-8, p53, mdm2, and p14 ARF . No significant relation was detected between p53, mdm2 expression, and pathological stage or grade. However, it was found that the recurrence was related with both p53 and mdm2 positivity or either p53 or mdm2 positivity. It is well known that up to 70% of patients with pTa and pT1tumors show local recurrence despite to standardized treatment of UC. [23] We thought that the simultaneous assessment of p53 and mdm2 expression might be a useful prognostic parameter for the determination of recurrence in UC. p14 ARF plays an important role in p53 pathway by binding to mdm2, the main effector of p53 degradation. [24] There are limited studies about the importance of p14 ARF expression in bladder cancer. Yurakh et al. [20] showed that a loss of p14 ARF expression was an independent prognostic factor for a shorter recurrence-free interval in UC. In the present study, p14 ARF expression was significantly related with nuclear caspase-8 expression although no significant relation was detected between p14 ARF protein expression and pathological stage or grade. It is well known that p14 ARF and caspase-8 are involved in apoptosis by different pathways. Taken together, these proteins might have affected each other through unknown processes which warrant further investigation.
Caspase-8 plays a crucial role as an initiator caspase in the extrinsic apoptotic pathway since its activation leads to apoptosis by the activation of caspase-3. [6, 25] Caspase-dependent apoptosis is the predominant form of cell death induced by anticancer agents and tumor cells that evade apoptosis can also become resistant to chemotherapy. [4, 26] Yin et al. [27] showed that caspase-8 expression did not significantly correlate with tumor grade, stage, and patient outcome in pTa/pT1 human urinary bladder UC. Interestingly, cytoplasmic caspase-8 expression was significantly higher in pT1 UCs while nuclear caspase-8 expression was significantly higher in pTa UCs. Cytoplasmic caspase-8 is an important factor in triggering apoptosis through death receptors. [13] The improvement of tumor cell migration and the inhibition of Fas-induced apoptosis as a nonapoptotic function of caspase-8 has been recently described in different experimental cancer cell lines. [28] [29] [30] To date, the role of cytoplasmic and nuclear caspase-8 have not been described in the pathogenesis of UC. Koschny et al. [28] demonstrated that low cytoplasmic and high nuclear caspase-8 expression significantly correlated with impaired survival after partial hepatectomy. They also reported that cytoplasmic caspase-8 could be an independent prognostic factor from tumor grade. In the present study, no significant relation was detected between cytoplasmic caspase-8 expression and progression and recurrence of the disease although cytoplasmic caspase-8 expression was significantly higher in pT1 UCs than in pTa UCs. It was also found that the expression of nuclear caspase-8 was significantly higher in pTa UCs than in pT1 UCs. Although the activity of caspase-8 in the control of apoptotic or nonapoptotic responses has still not been elucidated we believed that the staining localization of caspase-8 might especially useful in providing important information about the pathogenesis of UC.
CONCLUSIONS
We suggest that the cytoplasmic caspase-8 might help us to determine the high-grade Ta and T1 tumors represent a significant risk of tumor progression. In addition to, the present study demonstrated that the use of the protein panel including p53 and mdm2 in IHC might be an important tool for estimating the risk of recurrence in UC. Overall, to determine the altered patterns of protein panels may be critical to define the biological behavior of tumors such as prognosis, recurrence, and/or chemotherapy response in UC.
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